UPDATE: Evercore Group Reiterates Overweight Rating, Lowers PT on Applied Micro Circuits Corporation on New Focus on X-Gene

Loading...
Loading...
In a report published Wednesday, Evercore Group analyst Michael Lucarelli reiterated an Overweight rating on
Applied Micro Circuits Corporation
AMCC
, but lowered the price target from $15.00 to $13.00. In the report, Evercore Group noted, “While we are disappointed with the poor results and exceptionally weak guidance, the reset clears a path for all focus to be on growth areas of X-Gene, X-Weave, and embedded ARM over the coming quarters. The large revenue shortfall stemmed completely from the legacy PowerPC business while connectivity performed well and X-Gene revenues started earlier than anticipated. Importantly, the base business, even at this low revenue level, remains capable of supporting X-Gene and X-Weave investments ahead of meaningful XGene deployments that are on track to ship before year-end (Mar). Purchase orders for X-Gene continue to grow and backlog is building with interest across all targeted verticals which now include HPC. With X-Gene 1 production silicon shipping today and X-Gene 2 on track for 1H15, our thesis remains unchanged that the time to own APM for XGene is over the next 12-18mo when it is the only custom silicon shipping in the market. Lower PT to $13 from $15 but maintain OW.” Applied Micro Circuits Corporation closed on Tuesday at $9.67.
Loading...
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsEvercore GroupMichael Lucarelli
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...